11 results about "Targeted immunotherapy" patented technology

The present disclosure provides improved CD33 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

This invention belongs to the field of biomedical technology, specifically disclosing the application of cimicifuga in the preparation of drugs for treating periodontitis. Specifically, it relates to the application of cimicifuga in the preparation of drugs for treating periodontitis; and the application of cimicifuga in the preparation of drugs for treating alveolar bone defects (periodontal bone defects) caused by periodontitis. It also relates to the application of cimicifuga in the preparation of products for inhibiting macrophage polarization towards M1 and / or promoting macrophage polarization towards M2 in a single macrophage system. In this disclosure, cimicifuga has no significant toxicity to macrophages and has high safety; it targets and regulates macrophage polarization, inhibiting periodontal inflammation at its source; it significantly reduces inflammatory infiltration and osteoclast formation in periodontal tissues, effectively alleviating alveolar bone defects; and it provides a novel targeted immunotherapy drug for periodontitis, expanding the clinical application of single traditional Chinese medicine monomers.

Embodiments of the present disclosure pertain generally to head and neck squamous cell carcinomas (HNSCCs) related to human papillomavirus subtype 16 (HPV16) infections. More particularly, the present disclosure provides novel immunogenic epitopes from HPV16 E2, E6 and E7 antigens restricted by common human leukocyte antigen (HLA) alleles for the diagnosis and treatment of HNSCC. The HPV16 epitopes identified in the present disclosure can be used in combination with blockade of HPV16+ HNSCC-specific checkpoints for targeted immunotherapy.

The present disclosure provides improved CD33 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

The present disclosure provides a virus like particle comprising a viral structural protein and a galectin epitope peptide, and a composition or vaccine comprising thereof, its use in a medicine, particularly in an immunotherapy.

The invention discloses a chemical crosslinking type bacterial outer membrane vesicle-PD-L1 composite nano preparation as well as a preparation method and application of the chemical crosslinking type bacterial outer membrane vesicle-PD-L1 composite nano preparation. According to the nano preparation, outer membrane vesicles derived from fecal bacillus rodent are taken as a delivery carrier, and an anti-PD-L1 antibody is stably coupled to the surfaces of the vesicles under the chemical cross-linking action of DSPE-PEG-NHS, so that the composite nano preparation MVs / alpha-PD-L1 is formed; in-vitro experiments show that the composite nano preparation can significantly inhibit the activity of breast cancer cells and induce apoptosis of the breast cancer cells; in a 4T1 in-situ breast cancer mouse model, tumor growth can be effectively inhibited, a tumor immune microenvironment can be remodeled, the biological safety is good, and a safe and effective novel delivery system is provided for targeted immunotherapy of breast cancer.

Provided are novel human-derived monoclonal neutralizing Nogo-A specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Polynucleotides, vectors, host cells and kits related to the Nogo-A specific antibodies are also provided. The antibodies, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for Nogo-A targeted immunotherapy and diagnosis, respectively.

The present disclosure provides improved CLL-1 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory discase, and immunodeficiency, or condition associated therewith.

The invention discloses a curative effect prediction method for a hepatocellular carcinoma patient receiving TACE combined target immunotherapy, and relates to the field of medical data processing, and the method comprises the steps: inputting energy spectrum CT data and perfusion CT data into a first deep learning model, predicting a first curative effect prediction result of the target hepatocellular carcinoma patient receiving the TACE combined target immunotherapy through the first deep learning model; inputting the image data into a second deep learning model, and predicting a second curative effect prediction result of the target hepatocellular carcinoma patient receiving the TACE combined target immunotherapy through the second deep learning model; inputting the clinical examination data into a third deep learning model, and predicting a third curative effect prediction result of the target hepatocellular carcinoma patient receiving the TACE combined target immunotherapy through the third deep learning model; and performing cross-modal fusion on the first curative effect prediction result, the second curative effect prediction result and the third curative effect prediction result to obtain a target curative effect prediction result of the target hepatocellular carcinoma patient receiving the TACE combined target immunotherapy.

Disclosed are engineered cells comprising chimeric antigen receptors and uses thereof for treating prostate cancer.

Relapsed / refractory T-cell acute lymphoblastic leukemia (T-ALL) has a dismal outcome, and no effective targeted immunotherapies for T-ALL exist. The extension of chimeric antigen receptor T-cells (CARTs) to T-ALL remains challenging because the shared expression of target antigens between CARTs and T-ALL blasts leads to CARTs fratricide. CD1a is exclusively expressed in cortical T-ALLs, a major subset of T-ALL. The expression of CD1a is restricted to cortical thymocytes and neither CD34+ progenitors nor T-cells express CD1a during ontogeny, confining the risk of on-target / off-tumor toxicity. The present invention provides CARs comprising a CD1a-targeting moiety which may be transduced or transformed into T cells. The resultant CARTs are suitable for the treatment of cortical T-ALLs.